Centene(US:CNC) GlobeNewswire News Roomยท2025-07-20 14:39Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to significant stock price declines [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Centene to contact them for legal options, particularly those who purchased securities between December 12, 2024, and June 30, 2025 [1][3]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Company Performance and Stock Impact - Centene provided positive statements to investors while concealing adverse facts about its enrollment and morbidity rates, leading to a significant loss of investor trust [5]. - On July 1, 2025, Centene withdrew its 2025 guidance, stating that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% in just one day [6].